This study aims to evaluate the effects of Munziq and Mushil therapy on asthma patients with abnormal savda syndrome. During March 2012 to October 2013, 75 asthma patients with abnormal savda syndrome from Rrespiratory Department of the First Affiliated Hospital of Xinjiang Medical University were randomly assigned to the treatment group (n=38) and control group (n=37). The control group received budesonide and formoterol fumarate powder for inhalation (symbicort turbuhaler), and the treatment group received traditional Uyghur medicine combined with those for the control group; The course of treatment was one month. The day and night clinical symptoms of asthma, ACT grade and asthma quality of life questionnaire (AQLQ) grade were observed and compared. In one month, asthma was well controlled in 91.9% of patients in the control group and 94.8% of patients in the treatment group, but the difference was not significant statistically (P>0.05). Compared to the baseline, day and night symptom controlled scores and ACT scores increased in both groups, but not statistically different in one month (P>0.05). The AQLQ grades of both groups were improved after one month treatment compared to the baseline, and the mean difference was significantly different between the two groups (P<0.05). Health related quality of life subscale such as exercise endurance, mentality status, reaction to stimulation and care to own health were significantly higher in the treatment group than in the control group. Traditional Uyghur medicine combined with western medicine showed similar effects in improving in ACT grades and AQLQ grades of asthma patients when compared to use of western medicine alone. However, use of traditional Uyghur medicine can improve health related quality of life of asthma patients when combined with western medicine, which was its advantage.

asthma with abnormal savda syndrome  /  traditional Uyghur medicine  /  day and night symptom controlled score  /  ACT grade  /  AQLQ grade